EverSource Wealth Advisors LLC Boosts Position in Edwards Lifesciences Co. (NYSE:EW)

EverSource Wealth Advisors LLC increased its holdings in Edwards Lifesciences Co. (NYSE:EW) by 27.6% in the fourth quarter, HoldingsChannel.com reports. The fund owned 1,304 shares of the medical research company’s stock after acquiring an additional 282 shares during the period. EverSource Wealth Advisors LLC’s holdings in Edwards Lifesciences were worth $97,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the stock. Sequoia Financial Advisors LLC lifted its holdings in Edwards Lifesciences by 17.0% in the fourth quarter. Sequoia Financial Advisors LLC now owns 8,078 shares of the medical research company’s stock worth $598,000 after buying an additional 1,176 shares during the period. Moors & Cabot Inc. boosted its position in shares of Edwards Lifesciences by 0.3% during the fourth quarter. Moors & Cabot Inc. now owns 54,589 shares of the medical research company’s stock valued at $4,041,000 after purchasing an additional 152 shares in the last quarter. Natural Investments LLC bought a new stake in shares of Edwards Lifesciences during the fourth quarter valued at approximately $392,000. Channing Capital Management LLC purchased a new stake in Edwards Lifesciences in the fourth quarter worth $9,281,000. Finally, Clare Market Investments LLC bought a new position in Edwards Lifesciences in the fourth quarter worth $254,000. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Down 0.5 %

Edwards Lifesciences stock opened at $70.31 on Wednesday. The stock has a market cap of $41.33 billion, a PE ratio of 10.09, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The stock has a fifty day moving average of $71.61 and a 200 day moving average of $70.35. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, sell-side analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Insider Activity

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 400 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $69.48, for a total transaction of $27,792.00. Following the sale, the vice president now owns 22,588 shares in the company, valued at approximately $1,569,414.24. This trade represents a 1.74 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Steven R. Loranger sold 5,739 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $76.42, for a total transaction of $438,574.38. Following the completion of the transaction, the director now owns 60,372 shares of the company’s stock, valued at approximately $4,613,628.24. The trade was a 8.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 51,303 shares of company stock valued at $3,715,776 in the last 90 days. Company insiders own 1.29% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on EW shares. Canaccord Genuity Group upped their target price on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a research report on Thursday, February 13th. Evercore ISI cut their price objective on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a report on Wednesday, February 12th. Royal Bank of Canada reiterated an “outperform” rating and set a $85.00 target price on shares of Edwards Lifesciences in a report on Wednesday, February 12th. Piper Sandler upped their price target on Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 12th. Finally, Citigroup lifted their price objective on Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have given a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $79.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.